B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

TACR1

MOLECULAR TARGET

tachykinin receptor 1

UniProt: P25103NCBI Gene: 686915 compounds

TACR1 (tachykinin receptor 1) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TACR1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Substance P3.4330
2Aprepitant3.0019
3Neurokinin2.087
4Neurokinin B1.956
5Amoxapine0.691
6Aripiprazole0.691
7Astemizole Antihistamine drug now withdrawn from0.691
8Carvedilol0.691
9Dextromethorphan Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of0.691
10Eledoisin0.691
11Fidaxomicin0.691
12Kassinin Dodecapeptide tachykinin found in0.691
13neurokinin 1 receptor antagonists0.691
14Ritonavir0.691
15Trazodone0.691

About TACR1 as a Drug Target

TACR1 (tachykinin receptor 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented TACR1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TACR1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.